Search
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [A254726,A254731] Olutasidenib inhibits the mutated IDH1 specifically, and provides a therapeutic benefit in IDH1-mutated cancers.
Ontuxizumab
go.drugbank.com/drugs/DB16270InvestigationalOntuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).
Pecavaptan
go.drugbank.com/drugs/DB16279InvestigationalPecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).
Praliciguat
go.drugbank.com/drugs/DB16300InvestigationalPraliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
GSK-2981278
go.drugbank.com/drugs/DB16319InvestigationalGSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Seviprotimut-L
go.drugbank.com/drugs/DB16328InvestigationalSeviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).
Synonyms: Seviprotimut L, Seviprotimut-LVixarelimab
go.drugbank.com/drugs/DB16350InvestigationalVixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Vonlerolizumab
go.drugbank.com/drugs/DB16352InvestigationalVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic
Razuprotafib
go.drugbank.com/drugs/DB16353InvestigationalRazuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.
BGB-DXP593
go.drugbank.com/drugs/DB16357InvestigationalBGB-DXP593 is a SARS-CoV-2 neutralizing antibody.